Flash methylation and GLC of diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin.

R. Hammer,B. Wilder,R. Streiff,A. Mayersdorf

DOI: https://doi.org/10.1002/JPS.2600600245

1971-02-01

Journal of Pharmacy and Science

Abstract:

What problem does this paper attempt to address?

Beneficial Properties and Mechanisms of Natural Phytochemicals to Combat and Prevent Hyperuricemia and Gout

Junhao Wu,Yasmin Alhamoud,Siyu Lv,Fengqin Feng,Jing Wang

DOI: https://doi.org/10.1016/j.tifs.2023.06.021

IF: 16.002

2023-01-01

Trends in Food Science & Technology

Abstract:Background: Hyperuricemia refers to a metabolic disorder associated with high serum uric acid levels and is regarded as a major risk factor not only for the development of gout but also for various chronic diseases. However, current clinical hypouricemic medications still have some undesired side effects and are contra-indicated by multiple comorbidities. Thus, the development of natural therapeutic products as novel, safe, and effective alternatives to pharmacological agents is urgently needed.Scope and approach: This review mainly focuses on the research progress of phytochemicals in the treatment of hyperuricemia and gout. Additionally, the chemical structure, specific mechanism, and effective dose of natural phytochemicals are comprehensively highlighted.Key findings and conclusions: Many in vivo and/or in vitro studies have indicated that phytochemicals derived from natural sources, including alkaloids, phenolic acids, and flavonoids, possess the beneficial properties of down-regulating uric acid levels and dissolving monosodium urate crystals. Therefore, they have great potential to be novel and safe agents that can prevent and combat hyperuricemia and gout.
Hyperuricemia and Nonalcoholic Fatty Liver Disease: from Bedside to Bench and Back

Marco Perez,Vic Froelicher

DOI: https://doi.org/10.1007/s12072-015-9682-5

IF: 9.029

2015-01-01

Hepatology International

Abstract:Uric acid is the end product of dietary or endogenous purines degradation, and hyperuricemia is one of the most common metabolic disorders. It has been widely accepted that hyperuricemia increases risks of gout, cardiovascular diseases, and type 2 diabetes. A growing body of evidence, comprising a great deal of cross-sectional studies and several prospective ones, also indicates that hyperuricemia is associated with increased prevalence, incidence and disease severity of non-alcoholic fatty liver disease (NAFLD). On the contrary, NAFLD can predict hyperuricemia as well. However, no causal relationship can be drawn from this point. With a well-established relationship between uric acid and NAFLD prevalence as well as disease severity in addition to the role of potential therapeutic target, the prognostic role of uric acid is also worth investigating. Further studies should focus on the prospective role of uric acid on NAFLD progression and its underlying mechanisms, as well as its clinical implications.
Physiology of Hyperuricemia and Urate-Lowering Treatments

Caroline L. Benn,Pinky Dua,Rachel Gurrell,Peter Loudon,Andrew Pike,R. Ian Storer,Ciara Vangjeli

DOI: https://doi.org/10.3389/fmed.2018.00160

IF: 3.9

2018-05-31

Frontiers in Medicine

Abstract:Gout is the most common form of inflammatory arthritis and is a multifactorial disease typically characterized by hyperuricemia and monosodium urate crystal deposition predominantly in, but not limited to, the joints and the urinary tract. The prevalence of gout and hyperuricemia has increased in developed countries over the past two decades and research into the area has become progressively more active. We review the current field of knowledge with emphasis on active areas of hyperuricemia research including the underlying physiology, genetics and epidemiology, with a focus on studies which suggest association of hyperuricemia with common comorbidities including cardiovascular disease, renal insufficiency, metabolic syndrome and diabetes. Finally, we discuss current therapies and emerging drug discovery efforts aimed at delivering an optimized clinical treatment strategy.

medicine, general & internal
[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy]

M S Eliseev,A M Novikova

DOI: https://doi.org/10.26442/00403660.2019.05.000232

2019-05-15

Abstract:Nowadays, there is increased interest in the connection of gout and asymptomatic hyperuricemia with comorbid conditions such as diabetes mellitus, cardiovascular diseases, hypertension, chronic kidney disease and other. Studies conducted over the past few decades suggest that not only gout, but also asymptomatic hyperuricemia can significantly worsen the prognosis in patients with cardiovascular diseases, as the deposition of urate crystals can be both an immediate cause and a factor in the progression of renal failure. In that way, the timely appointment of urate - lowering therapy and achieving the target serum uric acid level can not only affect joint damage, but also can significantly slow the progression of life - threatening comorbid conditions.
Anti-Inflammatory and Hypouricemic Effect of Bioactive Compounds: Molecular Evidence and Potential Application in the Management of Gout

Anna Scanu,Roberto Luisetto,Roberta Ramonda,Paolo Spinella,Paolo Sfriso,Paola Galozzi,Francesca Oliviero

DOI: https://doi.org/10.3390/cimb44110352

2022-10-25

Abstract:Gout is caused by the deposition of monosodium urate crystals in the joint and represents the most common form of inflammatory arthritis in men. Its prevalence is rising worldwide mainly due to the increase of risk factors associated with the disease, in particular hyperuricemia. Besides gout, hyperuricemia leads to an increased inflammatory state of the body with consequent increased risk of comorbidities such as cardiovascular diseases. Increasing evidence shows that bioactive compounds have a significant role in fighting inflammatory and immune chronic conditions. In gout and hyperuricemia, these molecules can exert their effects at two levels. They can either decrease serum uric acid concentrations or fight inflammation associated with monosodium urate crystals deposits and hyperuricemia. In this view, they might be considered valuable support to the pharmacological therapy and prevention of the disease. This review aims to provide an overview of the beneficial role of bioactive compounds in hyperuricemia, gout development, and inflammatory pathways of the disease.
Gout and hyperuricaemia: modifiable cardiovascular risk factors?

Michel Burnier

DOI: https://doi.org/10.3389/fcvm.2023.1190069

IF: 3.6

2023-05-25

Frontiers in Cardiovascular Medicine

Abstract:Gout and hyperuricaemia are two clinical situations associated with an elevated risk of developing cardiovascular (heart failure, myocardial infarction, stroke) and metabolic and renal complications. One reason is probably related to the fact that the prevalence of hyperuricaemia and gout is high in clinical situations, which themselves involve a high cardiovascular risk, such as hypertension, diabetes, chronic kidney disease or obesity. However, recent studies suggest that hyperuricaemia may promote cardiovascular complications independently of other cardiovascular risk factors, by inducing chronic inflammation, oxidative stress, and endothelial dysfunction. The questions that arise today concern primarily the treatment of asymptomatic hyperuricaemia. Should it be treated to decrease the patients' cardiovascular risk and if so, starting from which level and towards which target? There are now several pieces of evidence indicating that this might be useful, but data from large studies are not unanimous. This review will discuss this issue as well as new well-tolerated treatments, such as febuxostat or SGLT2 inhibitors, which lower uric acid levels, prevent gout and lower the risk of cardio-renal events.

cardiac & cardiovascular systems
Flux Reversal in Three-Rung Laddics

J. Baldwin

DOI: https://doi.org/10.1109/TEC.1962.5219429

1962-10-01

IRE Transactions on Electronic Computers

Abstract:When the flux in the driven branch of a multipath core is reversed most of it will return via the shortest return path in the core. A small fraction will return by the next shortest. The ratio of the flux change in the shortest path to that in the next shortest is called the branching ratio r. Experimental branching ratios are much larger than they reasonably should be. In this paper a magnetic circuit analysis which neglects leakage and reversible flux but includes the dependence of branch reluctance on flux is applied to the three-rung laddic. The calculations predict a branching ratio at infinite drive which is about a factor of two greater than might be naively expected. Except in special cases they predict that it should decrease monotonically with drive. Experimentally it may either increase, decrease, or saturate shortly after threshold. The experimental values are uniformly greater than the theoretical. It appears likely that the disparity between theory and experiment can be attributed to flux leakage during switching. This leakage may be minimized by silver plating the core. A remeasurement of the branching ratio as a function of drive and geometry seems to be indicated at the present time.
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

Claudio Borghi,Enrico Agabiti-Rosei,Richard J Johnson,Jan T Kielstein,Empar Lurbe,Giuseppe Mancia,Josep Redon,Austin G Stack,Konstantinos P Tsioufis

DOI: https://doi.org/10.1016/j.ejim.2020.07.006

Abstract:During the last century, there has been an increasing prevalence of hyperuricaemia noted in many populations. While uric acid is usually discussed in the context of gout, hyperuricaemia is also associated with hypertension, chronic kidney disease, hypertriglyceridaemia, obesity, atherosclerotic heart disease, metabolic syndrome, and type 2 diabetes. Here we review the connection between hyperuricaemia and cardiovascular, kidney and metabolic diseases. Contrary to the popular view that uric acid is an inert metabolite of purine metabolism, recent studies suggest serum uric acid may have a variety of pro-inflammatory, pro-oxidative and vasoconstrictive actions that may contribute to cardiometabolic diseases. Hyperuricaemia is a predictive factor for the development of hypertension, metabolic syndrome, type 2 diabetes, coronary artery disease, left ventricular hypertrophy, atrial fibrillation, myocardial infarction, stroke, heart failure and chronic kidney disease. Treatment with uric acid-lowering therapies has also been found to improve outcomes in patients with hypertension and kidney disease, in some but not all studies. In conclusion, uric acid is emerging as a potentially treatable risk factor for cardiometabolic diseases, and more clinical trials investigating the potential benefit of lowering serum uric acid are recommended in individuals with hyperuricaemia with and without deposition and concomitant hypertension, metabolic syndrome or chronic kidney disease.
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review

Robert Terkeltaub

DOI: https://doi.org/10.1007/s40265-023-01944-y

2023-10-12

Drugs

Abstract:Hyperuricemia with consequent monosodium urate crystal deposition leads to gout, characterized by painful, incapacitating inflammatory arthritis flares that are also associated with increased cardiovascular event and related mortality risk. This narrative review focuses on emerging pharmacologic urate-lowering treatment (ULT) and management strategies in gout. Undertreated, gout can progress to palpable tophi and joint damage. In oral ULT clinical trials, target serum urate of < 6.0 mg/dL can be achieved in ~ 80–90% of subjects, with flare burden reduction by 1–2 years. However, real-world ULT results are far less successful, due to both singular patient nonadherence and prescriber undertreatment, particularly in primary care, where most patients are managed. Multiple dose titrations commonly needed to optimize first-line allopurinol ULT monotherapy, and substantial potential toxicities and other limitations of approved, marketed oral monotherapy ULT drugs, promote hyperuricemia undertreatment. Common gout comorbidities with associated increased mortality (e.g., moderate–severe chronic kidney disease [CKD], type 2 diabetes, hypertension, atherosclerosis, heart failure) heighten ULT treatment complexity and emphasize unmet needs for better and more rapid clinically significant outcomes, including attenuated gout flare burden. The gout drug armamentarium will be expanded by integrating sodium-glucose cotransporter-2 (SGLT2) inhibitors with uricosuric and anti-inflammatory properties as well as clinically indicated antidiabetic, nephroprotective, and/or cardioprotective effects. The broad ULT developmental pipeline is loaded with multiple uricosurics that selectively target uric acid transporter 1 (URAT1). Evolving ULT approaches include administering selected gut anaerobic purine degrading bacteria (PDB), modulating intestinal urate transport, and employing liver-targeted xanthine oxidoreductase mRNA knockdown. Last, emerging measures to decrease the immunogenicity of systemically administered recombinant uricases should simplify treatment regimens and further improve outcomes in managing the most severe gout phenotypes.

pharmacology & pharmacy,toxicology
Hyperuricemia and its related diseases: mechanisms and advances in therapy

Lin Du,Yao Zong,Haorui Li,Qiyue Wang,Lei Xie,Bo Yang,Yidan Pang,Changqing Zhang,Zhigang Zhong,Junjie Gao

DOI: https://doi.org/10.1038/s41392-024-01916-y

2024-08-28

Abstract:Hyperuricemia, characterized by elevated levels of serum uric acid (SUA), is linked to a spectrum of commodities such as gout, cardiovascular diseases, renal disorders, metabolic syndrome, and diabetes, etc. Significantly impairing the quality of life for those affected, the prevalence of hyperuricemia is an upward trend globally, especially in most developed countries. UA possesses a multifaceted role, such as antioxidant, pro-oxidative, pro-inflammatory, nitric oxide modulating, anti-aging, and immune effects, which are significant in both physiological and pathological contexts. The equilibrium of circulating urate levels hinges on the interplay between production and excretion, a delicate balance orchestrated by urate transporter functions across various epithelial tissues and cell types. While existing research has identified hyperuricemia involvement in numerous biological processes and signaling pathways, the precise mechanisms connecting elevated UA levels to disease etiology remain to be fully elucidated. In addition, the influence of genetic susceptibilities and environmental determinants on hyperuricemia calls for a detailed and nuanced examination. This review compiles data from global epidemiological studies and clinical practices, exploring the physiological processes and the genetic foundations of urate transporters in depth. Furthermore, we uncover the complex mechanisms by which the UA induced inflammation influences metabolic processes in individuals with hyperuricemia and the association with its relative disease, offering a foundation for innovative therapeutic approaches and advanced pharmacological strategies.
A Review of Uric Acid, Crystal Deposition Disease, and Gout

Fernando Perez-Ruiz,Nicola Dalbeth,Tomas Bardin

DOI: https://doi.org/10.1007/s12325-014-0175-z

2014-12-23

Advances in Therapy

Abstract:There has been increased interest in gout in both academic and clinical practice settings. Several reasons may explain this. The prevalence of both hyperuricemia and gout has risen in the last decades in developed countries and therefore the burden of gout has increased. The association of hyperuricemia and gout with cardiovascular outcomes and the opportunity of further benefits of intervention on hyperuricemia have been recently highlighted in the literature. Imaging techniques have proven to be useful for detection of urate deposition, even prior to the first clinical symptoms, enabling the evaluation of the extent of deposition and providing objective measurement of crystal depletion during urate-lowering treatment. Treating to target is increasingly used as the approach to treatment of diverse diseases. Therefore, different targets have been recommended for different stages of the burden of disease and for different stages of treatment. The final strategic target, to which any effort should be taken into consideration, is to completely dissolve urate crystals in tissues and therefore avoid further symptoms and structural damage of involved musculoskeletal structures. In summary, evidence suggest that an early approach to the treatment of gout and associated comorbidities is advisable, that new imaging techniques may help to evaluate both the burden of deposition and response to urate-lowering treatment in selected patients, and finally that the final strategic objective of healthcare for patients with gout is to completely resolve urate crystal deposits.

pharmacology & pharmacy,medicine, research & experimental
Development and Evaluation of High Bioavailable Sustained-Release Nimodipine Tablets Prepared with Monolithic Osmotic Pump Technology.

Hua Kong,Fang-lin Yu,Yan Liu,Yang Yang,Ming-yuan Li,Xiaohui Cheng,Xiaoqin Hu,Xuemei Tang,Zhiping Li,X. Mei

DOI: https://doi.org/10.2174/1567201814666161109122840

Current Drug Delivery

Abstract:BACKGROUND Frequent administration caused by short half-life and low bioavailability due to poor solubility and low dissolution rate limit the further application of poorly water-soluble nimodipine, although several new indications have been developed. To overcome these shortcomings, sophisticated technologies had to be used since the dose of nimodipine was not too low and the addition of solubilizers could not resolve the problem of poor release. OBJECTIVE The purpose of this study was to obtain sustained and complete release of nimodipine with a simple and easily industrialized technology. METHODS The expandable monolithic osmotic pump tablets containing nimodipine combined with poloxamer 188 and carboxymethylcellulose sodium were prepared. The factors affecting drug release including the amount of solubilizing agent, expanding agent, retarding agent in core tablet and porogenic agent in semipermeable film were optimized. The release behavior was investigated both in vitro and in beagle dogs. RESULTS It was proved that the anticipant release of nimodipine could be realized in vitro. The sustained and complete release of nimodipine was also realized in beagles because the mean residence time of nimodipine from the osmotic pump system was longer and Cmax was lower than those from the sustained-release tablets in market while there was no difference in AUC(0-t) of the monolithic osmotic pump tablets and the sustained release tablets in market. CONCLUSION It was reasonable to believe that the sustained and complete release of poorly watersoluble nimodipine could be realized by using simple expandable monolithic osmotic pump technology combined with surfactant.
On the stability of the solution in an optimal control problem for a Schrödinger equation

M. Subaşi,H. Durur

DOI: https://doi.org/10.1016/j.amc.2014.10.069

IF: 4.397

2014-12-15

Applied Mathematics and Computation

Abstract:
Hyperuricemia – consequences of not initiating therapy. Benefits and drawbacks of treatment

Igor Domański,Aleksandra Kozieł,Natalia Kuderska,Paulina Wójcik,Tomasz Dudzik,Łucja Dudzik

DOI: https://doi.org/10.5114/reum/189998

2024-07-01

Rheumatology

Abstract:Hyperuricemia, characterized by elevated levels of uric acid in the body, is associated with several health risks, including gout, urolithiasis and cardiovascular disease. Although treatment options are available, they can lead to hypersensitivity reactions, particularly with allopurinol therapy. This paper provides a comprehensive review of the consequences of hyperuricemia, the need for treatment and the potential adverse effects of allopurinol, illustrated by a case study. The study highlights the importance of careful consideration before initiating therapy, particularly in patients with comorbidities and concomitant medication. It emphasizes the need for vigilant monitoring and individualized treatment approaches to reduce adverse effects. In addition, genetic factors, particularly HLA-B*5801, play an important role in determining susceptibility to allopurinol hypersensitivity reactions. This paper highlights the importance of informed decision making in the management of hyperuricemia to optimize patient outcomes while minimizing the risks associated with treatment.

rheumatology
The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems

Davide Agnoletti,Arrigo F G Cicero,Claudio Borghi,Arrigo F.G. Cicero

DOI: https://doi.org/10.1016/j.ccl.2021.04.009

IF: 2.41

2021-08-01

Cardiology Clinics

Abstract:The description of gout dates back almost 5000 years, and scientific interest in uric acid increased when it was found to be involved in the pathogenesis of gout. Since then, many basic and clinical studies have assessed the implications of uric acid for the oxidative system, inflammation, and cardiovascular and renal outcomes. Uric acid-lowering therapy failed to improve clinical hard outcomes in asymptomatic hyperuricemia, and it is retained in symptomatic hyperuricemia. Dietary and lifestyle modifications are critical to manage hyperuricemia. More studies are warranted to investigate the role of uric acid-lowering drugs on cardiovascular outcomes.

cardiac & cardiovascular systems
A glance into the future of gout

Francisca Sivera,Mariano Andres,Nicola Dalbeth

DOI: https://doi.org/10.1177/1759720X221114098

2022-07-29

Therapeutic Advances in Musculoskeletal Disease

Abstract:Therapeutic Advances in Musculoskeletal Disease, Volume 14, Issue , January-December 2022. Gout is characterized by monosodium urate (MSU) crystal deposits in and within joints. These deposits result from persistent hyperuricaemia and most typically lead to recurrent acute inflammatory episodes (gout flares). Even though some aspects of gout are well characterized, uncertainties remain; this upcoming decade should provide further insights into many of these uncertainties. Synovial fluid analysis allows for the identification of MSU crystals and unequivocal diagnosis. Non-invasive methods for diagnosis are being explored, such as Raman spectroscopy and imaging modalities. Both ultrasound and dual-energy computed tomography (DECT) allow the detection of MSU crystals; this not only provides a mean of diagnosis, but also has furthered gout knowledge defining the presence of a preclinical deposition in asymptomatic hyperuricaemia. Scientific consensus establishes the beginning of gout as the beginning of symptoms (usually the first flare), but the concept is currently under review. For effective long-term gout management, the main goal is to promote crystal dissolution treatment by reducing serum urate below 6 mg/dL (or 5 mg/dL if faster crystal dissolution is required). Current urate-lowering therapies' (ULTs) options are limited, with allopurinol and febuxostat being widely available, and probenecid, benzbromarone, and pegloticase available in some regions. New xanthine oxidase inhibitors and, especially, uricosurics inhibiting urate transporter URAT1 are under development; it is probable that the new decade will see a welcomed increase in the gout therapeutic armamentarium. Cardiovascular and renal comorbidities are common in gout patients. Studies determining whether optimal treatment of gout will positively impact these comorbidities are currently lacking, but will hopefully be forthcoming. Overall, the single change that will most impact gout management is greater uptake of international rheumatology society recommendations. Innovative strategies, such as nurse-led interventions based on these recommendations have recently demonstrated treatment success for people with gout.

rheumatology
Impact of Hyper- and Hypo-Uricemia on Kidney Function

Junichiro Miake,Ichiro Hisatome,Katsuyuki Tomita,Tadahiro Isoyama,Shinobu Sugihara,Masanari Kuwabara,Kazuhide Ogino,Haruaki Ninomiya

DOI: https://doi.org/10.3390/biomedicines11051258

IF: 4.757

2023-04-24

Biomedicines

Abstract:Uric acid (UA) forms monosodium urate (MSU) crystals to exert proinflammatory actions, thus causing gout arthritis, urolithiasis, kidney disease, and cardiovascular disease. UA is also one of the most potent antioxidants that suppresses oxidative stress. Hyper andhypouricemia are caused by genetic mutations or polymorphism. Hyperuricemia increases urinary UA concentration and is frequently associated with urolithiasis, which is augmented by low urinary pH. Renal hypouricemia (RHU) is associated with renal stones by increased level of urinary UA, which correlates with the impaired tubular reabsorption of UA. Hyperuricemia causes gout nephropathy, characterized by renal interstitium and tubular damage because MSU precipitates in the tubules. RHU is also frequently associated with tubular damage with elevated urinary beta2-microglobulin due to increased urinary UA concentration, which is related to impaired tubular UA reabsorption through URAT1. Hyperuricemia could induce renal arteriopathy and reduce renal blood flow, while increasing urinary albumin excretion, which is correlated with plasma xanthine oxidoreductase (XOR) activity. RHU is associated with exercise-induced kidney injury, since low levels of SUA could induce the vasoconstriction of the kidney and the enhanced urinary UA excretion could form intratubular precipitation. A U-shaped association of SUA with organ damage is observed in patients with kidney diseases related to impaired endothelial function. Under hyperuricemia, intracellular UA, MSU crystals, and XOR could reduce NO and activate several proinflammatory signals, impairing endothelial functions. Under hypouricemia, the genetic and pharmacological depletion of UA could impair the NO-dependent and independent endothelial functions, suggesting that RHU and secondary hypouricemia might be a risk factor for the loss of kidney functions. In order to protect kidney functions in hyperuricemic patients, the use of urate lowering agents could be recommended to target SUA below 6 mg/dL. In order to protect the kidney functions in RHU patients, hydration and urinary alkalization may be recommended, and in some cases an XOR inhibitor might be recommended in order to reduce oxidative stress.
A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract.

R. Geckler

IF: 3.637

1994-07-01

Clinical Therapeutics

Abstract:Ampicillin/sulbactam (1 to 2 g ampicillin and 0.5 to 1 g sulbactam, administered intravenously once every 6 hours) and cefuroxime (750 mg to 1.5 g, administered intravenously once every 8 hours) were compared to determine their efficacy and safety in treating patients with lower respiratory tract infections of bacterial etiology. Nineteen of the 41 patients treated with ampicillin/sulbactam and 18 of the 44 patients treated with cefuroxime were assessable for efficacy. The clinical responses to the 2 treatments were comparable: 5 (26%) patients treated with ampicillin/sulbactam were cured and 14 (74%) were improved. Five (28%) patients who received cefuroxime were cured, 12 (67%) were improved, and treatment failed in 1 patient (6%) (P = 0.569). Similarly, no significant difference was noted between the bacteriologic responses to the two antimicrobials (P = 0.486). All isolates from the patients treated with ampicillin/sulbactam were eradicated, as were all isolates in 17 (94%) of the patients treated with cefuroxime. A superinfection occurred in 1 (6%) patient who received cefuroxime. Adverse reactions were rare and occurred in 3 patients from each treatment group.
Disseminating Nursing Best Practices in Diabetes Home Care Utilizing Standardized Language within a Global Context

Grace Gao,I. Bihl,K. Monsen

Abstract:SPECIAL CONSIDERATION Pressing needs have emerged to promote diabetes care in China along with its strong economic growth. As a major global health issue, diabetes is now becoming the world’s biggest epidemic in China. With 92 million people suffering diabetes, China has the most diabetes cases worldwide.1 Multi-partnership through global efforts has been implemented in the past to improve diabetic care in China based on a Share-Care Community Model.2 Community-based home care has been given a global focus on the initiation of best nursing practices through the employment of the standardized language, the Omaha System,3 by the Minnesota Omaha System Users Group. The purpose of this poster is to describe a translational process based on a conceptual model to disseminate the best practices in diabetes prevention and management in home care pathways through the Chinese language care plan.
[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review]

O I Mironova

DOI: https://doi.org/10.26442/00403660.2022.12.201999

2023-01-16

Abstract:Many studies have been conducted confirming the effect of uric acid (UA) on kidney function. It is obvious that there is a relationship between the effect of UA not only on kidney function, but also on the cardiovascular system, increasing cardiovascular risk. The review article provides basic information about the pathogenesis, principles and features of prescribing therapy to patients with chronic kidney disease (CKD) and cardiovascular disease. A lot of data currently indicates that hyperuricemia, both with and without crystal deposition, is associated with high cardiovascular risk and decreased kidney function. A number of studies and meta-analyses indicate that urate-reducing therapy prevents and slows down the decline in kidney function in patients with CKD, many of whom suffer from cardiovascular diseases or at least have several risk factors. Despite the fact that currently the guidelines for the treatment of CKD do not include a recommendation for the start of urate-lowering therapy, a large amount of data has been accumulated on the potential benefits of such treatment even in the absence of a diagnosis of gout. The preferred group of drugs for this group of patients are xanthine oxidase inhibitors, and for patients with eGFR below 30 ml/min/1.73 m2, it seems that allopurinol currently has larger evidence base for the efficacy and safety of prescribing.

Flash methylation and GLC of diphenylhydantoin and 5-(p-hydroxyphenyl)-5-phenylhydantoin.

Beneficial Properties and Mechanisms of Natural Phytochemicals to Combat and Prevent Hyperuricemia and Gout

Hyperuricemia and Nonalcoholic Fatty Liver Disease: from Bedside to Bench and Back

Physiology of Hyperuricemia and Urate-Lowering Treatments

[Comorbidity in gout and hyperuricemia: prevalence, causes, prospects of urate lowering therapy]

Anti-Inflammatory and Hypouricemic Effect of Bioactive Compounds: Molecular Evidence and Potential Application in the Management of Gout

Gout and hyperuricaemia: modifiable cardiovascular risk factors?

Flux Reversal in Three-Rung Laddics

Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease

Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review

Hyperuricemia and its related diseases: mechanisms and advances in therapy

A Review of Uric Acid, Crystal Deposition Disease, and Gout

Development and Evaluation of High Bioavailable Sustained-Release Nimodipine Tablets Prepared with Monolithic Osmotic Pump Technology.

On the stability of the solution in an optimal control problem for a Schrödinger equation

Hyperuricemia – consequences of not initiating therapy. Benefits and drawbacks of treatment

The Impact of Uric Acid and Hyperuricemia on Cardiovascular and Renal Systems

A glance into the future of gout

Impact of Hyper- and Hypo-Uricemia on Kidney Function

A comparison of ampicillin/sulbactam and cefuroxime in the treatment of patients with bacterial infections of the lower respiratory tract.

Disseminating Nursing Best Practices in Diabetes Home Care Utilizing Standardized Language within a Global Context

[Hyperuricemia and kidney damage in patients with cardiovascular disease: A review]